650results about How to "Treatment safety" patented technology

The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of ankylosing spondylitis in a subject.

Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.

The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of psoriatic arthritis in a subject.

The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of ankylosing spondylitis in a subject.

This invention relates generally to methods and apparatus for utilizing energy, e.g., optical radiation, to treat various dermatological and cosmetic conditions. A handheld dermatological device that facilitates viewing and measuring parameters of a treatment area before, during, and after application of a treatment modality, and methods of use therefor, are disclosed. The device can include a deflective device that can steer radiation to control a target position of the radiation. The device can also include a control device to allow a user to control the radiation through manipulation of the deflective device.

A method and apparatus for generating electromagnetic fields for healing. A device preferably includes a microcontroller and associated memory, a wire coil in electrical communication with a driving circuit that is controlled by the microcontroller in accordance with a program stored in the associated memory, wherein the driving circuit is effective to produce a pulsed DC output having a frequency in the range of about 0-45 Hz, more preferably in the range of 0.5-14.1 Hz and most preferably around 9.6 Hz. A user interface is provided for selecting one of a plurality of modes of operation and a port (e.g., a USB port) is provided to allow the program stored in the associated memory to be modified by way of a computer, memory card or the Internet. In another embodiment, the apparatus takes the form of a medallion that can be worn around a user's neck or strategically placed on a user's body or embedded in other user hardware such as a combat or racing helmet.

The present invention relates to a method of treating, reducing, inhibiting, preventing and/or reversing cutaneous facial flushing caused by abnormal, endogenously-induced vasomotor instability associated with, but not limited to acne rosacea, menopause-associated hot flashes, hot flashes resulting from orchiectomy or ingestion of substances capable of inducing a cutaneous facial flushing reaction (e.g.: alcohol, chocolate, spices) by topical dermatological application of an effective dose of a composition comprising at least one α₂ adrenergic receptor agonist (such as a (2-imidazolin-2-ylamino) quinoxaline derivative such as brimonidine tartrate)and a suitable carrier.

An intraocular lens having an anterior lens member (48) presenting an anterior light-converging optic (52) and a posterior lens member (50) presenting a posterior light-diverging optic (68) for magnifying an observed image onto large regions of the retina (32) to permit central focus in patients suffering from AMD and a method of implanting the lens into the human eye (10). The anterior light-converging optic (52) is operably coupled with a flexible body (58) which extends radially therefrom and presents opposing bights (62) presenting termini (66) when the lens is viewed in cross-section. The posterior light-diverging optic (68) is operably coupled with an annular flange (76) which is arcuate in cross-section and mates with termini. Both the anterior and the posterior lens members (48, 50) have positioning holes (70, 80) formed therein permitting surgical implantation thereof. The IOL (46) is constructed of a flexible synthetic resin material such as polymethylmethacrylate and permits focusing upon objects located near to and far from the viewer.

A pneumatic system consists of an inflatable/deflatable article, for example, a compression garment (21) connected to a pump (20) by connectors (12 and 11), respectively. The connector (12) attached to the garment (21) carries an RFID transponder (30) and a corresponding radio circuit (31) is located within the pump (20). In use, the transponder (30) transmits and receives information to and from the pump radio circuit (31). The information exchanged is used by the pump control system to activate the pump and to operate the pump to provide the particular operating parameters for that garment, for example, pressure, inflation/deflation cycle, duration of treatment, etc.

A medical filtering machine for the hemodialysis is composed of main body with console panel, blood loop consisting artery loop and vein loop, liquid-supplementing loop, water channel system and operation-control system. Said water channel system consists of reverse osmosis jointer, heat exchanger, heater, gear pump, deaerating unit, two concentrated liquid pumps, mixer, ion concentration monitor, volume balance and ultrafiltration unit, and endotoxin filter.

The invention provides methods and formulations for treating and preventing acute coronary syndromes. The methods of the instant invention provide safe and effective doses of an Apolipoprotein A-I Milano: phospholipid complex to reduce and stabilize atherosclerotic plaque. Pharmaceutical formulations of the Apo A-I Milano:phospholipid complexes are also provided.

Provided a method for treating hardly-decomposable-substance-containing water, in which hardly decomposable substances such as dioxins, contained in contaminated water (treatment raw water) are concentrated and rendered harmless by providing the steps of (B) adding an adsorbent to water containing a hardly decomposable substance (treatment raw water) to cause the hardly decomposable substance to be adsorbed on the adsorbent (adsorption treatment step), (C) separating a permeated liquid through a filter membrane to concentrate the adsorbent adsorbing the hardly decomposable substance (membrane filtering treatment step), and (D) chemically decomposing the hardly decomposable substance adsorbed on the concentrated adsorbent with a peroxide without any operation of desorption from the adsorbent (chemical decomposition step), and the method can be applied to water containing a reducing substance such as bisulfate that neutralize free chlorine and can render the hardly decomposable substances harmless efficiently at a low cost without being limited by properties of the hardly decomposable substances contained.

A medical image management system includes: a medical imaging device for imaging a patient to receive a medical treatment and creating a medical moving picture; and recording means for recording the medical moving picture imaged by the medical imaging device. The system further includes: measurement means for measuring biological information on a person who performs the medical treatment; and index addition means for adding an index to the medical moving picture recorded in the recording means, according to the measurement result obtained by the measurement means. By providing this system, it is possible to add an index to the medical moving picture recorded, according to the change of the biological information on the person who performs medical treatment on a patient.

A method of dissecting urethra obstructing tissue. The method includes capturing urethra obstructing tissue between portions of an implant and applying pressure on the tissue caught between the portions of the implant, for longer than 1 hour, until the tissue dies or falls off.

Compounds represented by general formula (1) or salts thereof which have a matrix metalloprotease inhibitory activity and are useful as drugs, wherein the rings A and B represent each an optionally substituted homocycle or heterocycle, etc.; R1s are the same or different and each represents hydrogen, optionally substituted hydrocarbyl, acyl, etc.; X1 represents a bond, optionally substituted divalent aliphatic hydrocarbyl, etc.; X2 represents a bond, optionally substituted divalent aliphatic hydrocarbyl, -O-, etc.; Ys are the same or different represents hydrogen, optionally substituted hydrocarbyl, oxo, etc.; m is 0 or 1; n is an integer of 1 to 3; q1 is an integer of 1 to 2n+4; and q2 is an integer of 0 to 2n+3, provided that q1+q2 is 2n+4.

The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs.

A mobile liquid treatment station and operation methods are disclosed, the station having a mobile treatment unit and separate mobile treatment management unit. A plurality of serial containment compartments at the treatment unit for performance of chemical dosing and solids separation are provided and are monitored with sensors. The management unit includes a plurality of chemical dosing platforms, and a power and processing assembly. A bus links the units for data and control signal transfer and chemical feed lines are connected between the units for transfer of dosing chemicals.

A pneumatic system consists of an inflatable/deflatable article, for example, a compression garment connected to a pump by connectors, respectively. The connector attached to the garment carries an RFID transponder and a corresponding radio circuit is located within the pump. In use, the transponder transmits and receives information to and from the pump radio circuit. The information exchanged is used by the pump control system to activate the pump and to operate the pump to provide the particular operating parameters for that garment, for example, pressure, inflation/deflation cycle duration of treatment, etc. The pneumatic system may include communication means for the pump, such as a radio circuit, that is located remote from the pump. Also, the pneumatic system may include a support mechanism that functions both as a handle and a hook.

Devices, systems, and methods for accessing tissue, including the internal and external tissues of the heart, are disclosed. At least some of the embodiments disclosed herein provide access to the external surface of the heart through the pericardial space for localized delivery of leads to the heart tissue. At least some of the embodiments disclosed herein provide access to the pericardial space for removal of accumulated fluid. In addition, various disclosed embodiments provide devices, systems, and methods for engaging a tissue, for removing fluid from a space within a body, and for the delivery of substances to a targeted site for therapeutic purposes.